Organization | Bioverativ Therapeutics Inc.

Bioverativ Therapeutics Inc. Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Waltham MA United States (2017)

Status: Acquired by Sanofi-Aventis (2018)

Organization Overview

First Clinical Trial

2017

NCT00716716

First Marketed Drug

2017

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix)

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Bioverativ Therapeutics Inc. | Bioverativ Therapeutics, Inc. | BIOVERATIV THERAPEUTICS INC

Active Ingredients

Marketed Drugs (3)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (2014)

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix) (2014 NDA)

sutimlimab (Enjaymo) (2022)

Drugs in Phase 4 Trials (1)

antihemophilic factor viii (Recombinant) (Adynovate) (4 trials)

Drugs in Phase 3 Trials (6)

antihemophilic factor viii human (Hemofil M) (2 trials)

antihemophilic factor viii (Recombinant), Fc-fusion protein (Eloctate) (7 trials)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

coagulation factor ix (Recombinant), Fc-fusion protein (Alprolix) (6 trials)

human coagulation factor ix (Mononine) (1 trial)

sutimlimab (Enjaymo) (2 trials)

Drugs in Phase 2 Trials (2)

bivv001 (Advate) (1 trial)

st-400 (1 trial)

Drugs in Phase 1 Trials (1)

Key: Bioverativ Therapeutics Inc. (0) Acquired (1)

tnt009 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia, Hemolytic, Autoimmune (Phase 3)

beta-Thalassemia (Phase 2)

Hemophilia A (Phase 4)

Hemophilia B (Phase 3)

Menorrhagia (Phase 1)

Thalassemia (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 19
# of Trial APIs: 10